Introduction
============

The potential for drug metabolism varies from one individual to another. Therefore, drug metabolism capacity is a factor determining whether a drug produces pharmacological or adverse effects. Drug metabolism is classified into phase 1 and phase 2 reactions. The major reaction of phase 1 is oxidation in which cytochrome P450 (CYP) plays a key role ([@B4]). Of all the enzymes including phase 2, UDP-glucuronosyltransferase (UGT) is mediating conjugation with glucuronic acid supplied from a cofactor (UDP-glucuronic acid, UDPGA) ([@B22]). CYP and UGT are bound to the endoplasmic reticulum membrane, and their catalytic domains are localized in the cytosolic and luminal sides, respectively ([@B23]; [@B28]). These enzymes have long been considered to work separately. However, we have shown that several UGTs can be trapped by a CYP1A1-immobilized affinity column ([@B27]). Moreover, our previous studies have shown that interaction between CYP3A4 and UGT2B7 alters the regio-selectivity of UGT2B7-catalyzed morphine glucuronidation ([@B25], [@B26]). Furthermore, CYP3A4 alters the function of UGT1A subfamily isoforms in an isoform and allelic variant specific fashion ([@B7]). Rat UGTs are efficiently co-immunoprecipitated with anti-CYP3A antibody and the CYP3A-UGT complex is catalytically active for 4-methylumbelliferone glucuronidation ([@B6]). Although the mechanisms of the interaction between CYP3A and UGT have not been clarified, the J-helix region of CYP3A4 is a candidate region involved in the interaction with UGT2B7 ([@B26]). The domain(s) of UGT2B7 involved in the interaction with CYP3A4 has also been reported ([@B16]). It is suggested that the hydrophobic regions at both the carboxyl terminal and luminal anchoring segment of UGT2B7 are crucial. However, further details about the interaction remain to be clarified.

Many UGTs have consensus sequences for *N-*glycosylation ([@B12],[@B13]; [@B1]; [@B21]; [@B19]). The sequence can be generalized as NX(S/T), where X is any amino acid except proline, and approximately 70-90% of this sequence is glycosylated at its asparagine (N) residue ([@B2]). Earlier studies have reported that *N-*glycosylation affects the enzyme activity of UGTs ([@B12],[@B13]; [@B1]; [@B21]; [@B19]). We have reported that CYP3A4 interacts with UGT1A1, 1A6, 1A7, and 2B7 ([@B25]; [@B7]). All of these UGT isoforms possess potential *N-*glycosylation sites. However, the role of *N-*glycosylation of UGT in the interaction with CYP3A is unknown. Although the inhibition of *N-*glycosylation reduces UGT1A9 activity, deglycosylation of the mature form (*N-*glycosylated form) did not affect its catalytic properties ([@B21]). Thus, *N-*glycosylation has been suggested to be important for the protein folding of UGT. However, multiple mutations of the three *N-*glycosylation sites on UGT2B7 have different effects on substrate specificities ([@B19]). Because of the important roles of *N-*glycosylation in UGT folding and function, we hypothesized that the *N-*glycosylation of UGT affects the interaction between CYP3A and UGT. To address this issue, we focused on rat UGT2B3 ([@B11]) which does not possess potential glycosylation sites. We examined whether CYP3A1 modulates UGT2B3 and whether the introduction of *N-*glycosylation to UGT2B3 affects the CYP3A-dependent modulation of the UGT function.

Materials and Methods {#s1}
=====================

Materials
---------

4-Methylumbelliferone (4-MU) and alamethicin were purchased from Sigma-Aldrich (St. Louis, MO, USA). UDP-Glucuronic acid (UDPGA) trisodium salt and 4-MU-β-[D]{.smallcaps}-glucuronide were obtained from Nakalai Tesque (Kyoto, Japan). Endoglycosidase H (EndoH) was purchased from New England Biolabos (Beverly, MA, USA). All other reagents were of the highest grade commercially available.

Animals
-------

Animal experiments in this study were conducted following the approval of the Ethics Committee for Animal Experiments of Kyushu University. Male Wistar rats (7 weeks-old) were obtained from Charles River Japan (Tokyo, Japan) and were maintained for one week with free access to water and a suitable diet under a 7 a.m. to 7 p.m. light/dark cycle. For isolation of total RNA, liver tissue was quickly cut into small fragments, immediately immersed in liquid nitrogen, and stored at -80°C until required.

Expression System
-----------------

Baculovirus for expressing CYP3A1 and UGT2B3 in Sf-9 cells was prepared using a Bac-to-Bac system (Invitrogen). CYP3A1 cDNA was subcloned from P91023(B) ([@B20]) into pFastBac1 vector at an *EcoR*I site. The sequencing reaction was carried out using a Big Dye^®^ Terminator v3.1 Cycle Sequencing Kit (Life Technologies). Then, cDNA sequences were confirmed by an ABI 3130xl Genetic Analyzer. CYP3A1 has two synonymous and one non-synonymous nucleotide substitutions: C1035G, G1074A, and T1055A, respectively, when compared with the database ([@B3]; GenBank accession M10161). T1055A causes an amino acid substitution, M352K, and this CYP3A1 is known to be catalytically active ([@B20]). It was used as the CYP3A1 in this study.

UGT2B3 cDNA was amplified from the total RNA of Wistar rat liver by a reverse transcription-polymerase chain reaction (RT-PCR), and cloned into pFastBac1. Isolation of total RNA and the RT-reaction were carried out by a method previously reported ([@B17]). To amplify the cDNA, nested PCR with two primer sets was used. The primer set for the first round PCR was UGT2B3(-20,-1)F1, 5′- TAA GGA TTT TGA TTT TTA AG-3′ and UGT2B3(1647,1628)R1, 5′-CAT AAA T TA GAA TGA GGC TG-3′. The primer set for the second round PCR was PstI-UGT2B3(-5,15)F2, 5′-AA[C TGC AG]{.ul}T TAA GAT GCC TGG GAA GTG G-3′, and PstI-UGT2B3(1615, 1596)R2, 5′-AA[C TGC AG]{.ul}T GTA GTG CAT TGT AA ATG AG-3′ with restriction sites (*Pst*I) underlined. The PCR was carried out with LA-Taq DNA polymerase (TaKaRa Bio, Kyoto) using the manufacturer's recommended protocol with the following components: 1xLA-Taq buffer, 2 mM MgCl~2~, 2.5 mM each dNTP, the primers F1 and R1 (5 μM each) and the cDNA in 100 μL (first round PCR). The amplification was carried out using the PROGRAM TEMP CONTROL SYSTEM PC-800 (ASTEC, Fukuoka, Japan) with 94°C, 4 min-(94°C, 1 min, 50°C, 1 min, 72°C, 2 min)×30 cycles-72°C, 20 min --4°C, ∞. The second round PCR was carried out as above but using primers F2 and R2. The resulting PCR products were restricted with PstI and cloned into pFastBac1. The sequence was confirmed by DNA sequencing as described above. UGT2B3 has a non-synonymous nucleotide substitution, T1498A, which causes a single amino-acid change, S500T. We used this as a wild-type UGT2B3 in this study.

*Escherichia coli* DH10Bac was transformed either with pFastBac1 plasmid carrying UGT2B3 or CYP3A1 cDNA to prepare recombinant bacmid DNA. Production and amplification of recombinant baculovirus and expression of recombinant proteins in Sf-9 cells were carried out according to the method described previously ([@B7]).

The Introduction of a Potential *N-*Glycosylation Site into UGT2B3
------------------------------------------------------------------

UGT2B3 exhibits 83% identity to UGT2B2 ([@B10]) in amino acid sequences. The Asn 316 of UGT2B2 is a potential site for glycosylation. Therefore, the Ser 316 of UGT2B3 was replaced with Asn by site-directed mutagenesis (SDM), and an expression system for the UGT2B3(S316N) mutant was constructed in a similar way as described above. The primers for the SDM were designed by Quick Change Primer Design (Agilent Technology). The primers used were UGT2B3(931, 964)(947G→A)SDM-F, 5′-GGG TCA ATG GTC AGC AAC ATG ACA GAA GAA AAG G-3′ and UGT2B3(964, 931)(947C→T)SDM-R, 5′-CCT TTT CTT CTG TCA TGT TGC TGA CCA TTG ACC C-3′. The procedures were carried out according to the manufacturer's recommendations. The introduction of the mutation at the appropriate position and the absence of other unwanted mutations were confirmed by DNA sequencing.

Kinetic Analysis
----------------

The kinetic analysis was performed using 100 μg microsomal protein. The amount of microsomal protein used was unified by adding control baculosomes. The activity of UGT2B3-catalyzed glucuronidation was determined by high-performance liquid chromatography (HPLC) with 4-MU as a substrate ([@B5]). The microsomes and alamethicin were mixed and preincubated for 30 min on ice. The assay was started by adding UDPGA and incubation was performed for 60 min at 37°C. The reaction was stopped with 100 μL 1 M trichloroacetic acid (TCA). After chilling on ice for 30 min, the incubation mixture was centrifuged (15,000 rpm, 4°C, 10 min). The supernatant containing the 4-MU glucuronide formed was analyzed by HPLC with a fluorescence detector (Ex 315 nm, Em 375 nm).

Data Analysis
-------------

The kinetics fitted a Michaelis-Menten equation, and the kinetic parameters were calculated using GraphPad Prism software (GraphPad Software Inc., San Diego, CA, USA). The statistical difference in kinetic parameters between UGT2B3 single expression and UGT2B3-CYP3A1 dual expression was evaluated by repeating the extra sum-of-squares *F* test.

Immunoblotting
--------------

Proteins were determined by the method of [@B9] with bovine serum albumin as a standard. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed according to [@B29]. Proteins separated by SDS-PAGE were electroblotted to a polyviniliden difluoride membrane. UGT2B3 and UGT2B3(S316N) were detected by a goat anti-mouse low-pI form UGT antibody ([@B14]). CYP3A1 was detected by rabbit anti-CYP3A2 antibody ([@B18]). Immunochemical detection was conducted either with horseradish peroxidase (HRP)-conjugated secondary antibodies, HRP-rabbit anti-goat IgG (MP Biomedicals, Santa Ana, CA, USA), or HRP-donkey anti-rabbit IgG (GE Healthcare, Piscataway, NJ, USA). These were diluted 10,000- and 40,000-fold before use, respectively. Clarity Western ECL Substrate (Bio-Rad, Hercules, CA, USA) was used as the substrate of HRP, and the chemiluminescence emitted was analyzed by a ChemiDoc MP System (Bio-Rad).

His-Tag Pull-Down Assay
-----------------------

Introduction of hemagglutinin (HA)-tag at the carboxyl terminus of UGT2B3 was carried out by a two-step PCR. At the first step, primer HA(21,1)-UGT2B3(1590,1573)R, 5′-ATC TGG AAC ATC GTA TGG GTA CTC ATT CTT CAT TTT CTT-3′ and primer F2 were used. The PCR reaction was basically the same as that above except that pFastBac1-UGT2B3 was the template. In the second step, PstI-TCA-HA(27,1)R, 5′-AA[C TGC AG]{.ul}T CAA GGG TAA TCT GGA ACA TCG TAT GGG TA-3′ and primer F2 were used (Underline, *Pst*I site). In the second step, the PCR products of the first step were used as a template. The PCR products were restricted with PstI and cloned into pFastBac1. To construct HA-tagged UGT2B3(S316N), an SDM described above was carried out with pFastBac1-UGT2B3-HA. To construct hexa-histidine (His)~6~-tagged CYP3A1, PCR was carried out with the following primers: NotI-CYP3A1(-4,16)F, 5′-ATA AGA AT[G CGG CCG C]{.ul}AG GGA TGG ACC TGC TTT CAG-3′ and XhoI-CYP3A1-Histag(1510,1494)R, 5′-CCG [CTC GAG]{.ul} TCA GTG ATG GTG ATG GTG ATG TGA TCC AGT TAT GAT TTC A-3′ (Underlines: *Not*I and *Xho*I sites, respectively). The PCR products were purified and restricted with *Not*I and *Xho*I and then subcloned into pFastBac1 restricted with the same enzymes. Their recombinant baculovirus was prepared as described above. Sf-9 cells were transfected with the recombinant virus for either CYP3A1-(His)~6~ and/or UGT2B3-HA/UGT2B3(S316N). The resulting microsomes were solubilized with sodium cholate and the pulled down assays were carried out as described previously ([@B16]).

Modeling of the Structure of the UGTs
-------------------------------------

The models were constructed using Phyre^2^ (Protein Homology/Analogy Recognition Engine V 2.0) web server, <http://www.sbg.bio.ic.ac.uk/phyre2/html/> ([@B8]) with UGT2B7 (amino acid residue from 285 to 450) as a template ([@B15]). Although the program is designed for prediction using multiple templates, only UGT2B7 was selected as a template in this case.

Results
=======

Expression of UGT2B3 and the Glycosylation Mutant, UGT2B3(S316N)
----------------------------------------------------------------

UGT2B3 was expressed in Sf-9 cells, and the protein band in the 50-60 kDa molecular mass range that was immunoreactive toward anti-mouse low pI form UGT antibody and was absent in control microsomes was judged to be UGT2B3 (**Figure [1A](#F1){ref-type="fig"}**). To introduce an *N-*glycosylated sugar chain to UGT2B3, we referred to UGT2B2 ([@B10]) which has a potential *N-*glycosylation site and exhibits high similarity to UGT2B3 in primary sequence. Then, the Ser316 of UGT2B3 was substituted to Asn to establish an expression system for UGT2B3(S316N). The immune-reactive band with higher molecular mass and absent in control microsomes was judged to be UGT2B3(S316N)(**Figure [1A](#F1){ref-type="fig"}**). Thus, the molecular mass was increased by the introduction of a potential glycosylation site suggesting newly introduced *N-*glycosylation. This was also supported by a reduction in size after EndoH-treatment (**Figure [1A](#F1){ref-type="fig"}**).

![**Immunoblots of the expression of UGT2B3, UGT2B3(S316N), and CYP3A1 in Sf-9 cells.** To obtain microsomes simultaneously expressing CYP3A1 and UGT2B3/UGT2B3(S316N), Sf-9 cells were transfected with recombinant baculovirus for CYP3A1 and UGT2B3/UGT2B3(S316N). The lanes labeled "UGT2B3" and "UGT2B3(S316N)" show microsomal samples of single transfected cells. The lanes labeled "UGT2B3+CYP3A1" and "UGT2B3(S316N)+CYP3A1" show double transfected cells. Baculosomes (5 μg protein) from UGT2B3 single-expressing Sf-9 cells were electrophoresed (SDS-PAGE). For baculosomes of CYP3A1-UGT2B3 co-expression systems, protein amounts equivalent to UGT2B3 for the single-expressing system were used. Similarly, baculosomes (3 μg protein) from UGT2B3(S316N) single-expressing Sf-9 cells were electrophoresed. For baculosomes of CYP3A1-UGT2B3(S316N) co-expression systems, protein amounts equivalent to UGT2B3(S316N) for the single-expressing system were used. Mock represents the baculosomes (10 μg protein) from Sf-9 cells infected with baculovirus without passenger DNA which served as controls. The proteins in the gel were electrically transferred to a polyvinilidene difluoride membrane, and blotted with goat anti-mouse low p*I* form UGT **(A-C)** and rabbit anti-CYP3A2 **(D,E)**, antibodies, respectively. In right panel of **(A)**, baculosomes (25 μg protein) from UGT2B3(S316N)-expressing Sf-9 cells were treated with Endoglycosidase H (EndoH, 500 U) at 37°C for 17 h. Four microgram protein of the digest was subjected to immunoblotting with goat anti-mouse low p*I* form UGT antibody as a primary antibody. Black and red arrow heads represent original and deglycosylated UGT2B3(S316N), respectively.](fphar-07-00427-g001){#F1}

Effect of Co-Expression of CYP3A1 on UGT2B3- and UGT2B3(S316N)-Catalyzed Glucuronidation
----------------------------------------------------------------------------------------

CYP3A1 was co-expressed in Sf-9 cells with UGT2B3 or UGT2B3(S316N). Sf-9 cells, the microsomes of which express UGT2B3 or UGT2B3(S316N) having a comparable band intensity to that in the single expression system, were selected and subjected to further investigation of their enzymatic properties (**Figures [1B--E](#F1){ref-type="fig"}**). The amount of UGT2B3 and microsomal protein used for the assay was also unified between the single and dual expression systems. For this, we rendered the protein level uniform with baculosomes obtained from Sf-9 cells infected with control baculovirus. When CYP3A1 was expressed together with UGT2B3, the *V*~max~ of UGT2B3-catalyzed 4-MU glucuronidation was significantly decreased (**Figure [2](#F2){ref-type="fig"}**; **Table [1](#T1){ref-type="table"}**). The kinetic profiles for both the single and double expression could be fitted to a Michaelis-Menten equation. When the 4-MU concentration was varied, the *V*~max~ was reduced significantly while the *K*~m~ was comparable (**Table [1](#T1){ref-type="table"}**). Furthermore, the same was also true for the kinetics by varying the UDPGA concentration (**Figure [3](#F3){ref-type="fig"}**; **Table [1](#T1){ref-type="table"}**). The *V*~max~ was lowered by CYP3A1 cotransfection while the *K*~m~ for UDPGA was comparable. Therefore, CYP3A1 suppressed the activity of UGT2B3 which lacks potential glycosylation sites. However, when CYP3A1 was expressed together with UGT2B3(S316N), the *V*~max~ of UGT2B3(S316N)-catalyzed 4-MU glucuronidation was significantly increased (**Figure [3](#F3){ref-type="fig"}**; **Table [2](#T2){ref-type="table"}**). The kinetic profiles for both single and double expression could be fitted to a Michaelis-Menten equation. When the 4-MU concentration was varied, the *V*~max~ was increased significantly while the *K*~m~ was comparable (**Table [2](#T2){ref-type="table"}**). Both the *V*~max~ and *K*~m~ of UGT2B3(S316N)-catalyzed 4-MU glucuronidation was significantly increased by varying the UDPGA concentration (**Figure [3](#F3){ref-type="fig"}**; **Table [2](#T2){ref-type="table"}**). In sharp contrast to the wild-type UGT2B3, co-expression of CYP3A1 increased UGT2B3(S316N) activity.

![**Michaelis-Menten plots of 4-MU glucuronidation catalyzed by UGT2B3 in the absence and presence of CYP3A1 co-expression.** The plots of UGT2B3 single- and UGT2B3-CYP3A1-dual are shown. The kinetics obtained by varying the 4-MU concentration **(A)** and UDPGA concentration **(B)** are shown. In **(A)**, the 4-MU concentration was varied over the range 10-1000 μM while the UDPGA concentration was fixed at 2 mM. In **(B)**, the UDPGA concentration was varied over the range 50 μM--3 mM while the 4-MU concentration was fixed at 1 mM. The total amount of protein added to the assay mixture was standardized at 100 μg. For this, when necessary, control baculosomes were added to the reaction mixture. Kinetic parameters were calculated by fitting the curve to a Michaelis-Menten equation, and they are listed in **Table [1](#T1){ref-type="table"}**.](fphar-07-00427-g002){#F2}

###### 

Kinetic parameters for 4-MU glucuronide formation catalyzed by Sf-9 microsomes expressing UGT2B3 alone and UGT2B3 + CYP3A1: kinetics by varying 4-MU or UDPGA concentration.

                                   *K*~m~ (μM)   *V*~max~ (pmol/min/mg protein)   CLint (μg/min/mg protein)
  -------------------------------- ------------- -------------------------------- ---------------------------
  By varying 4-MU concentration                                                   
  UGT2B3                           231 ± 31      682 ± 33                         2.95
  UGT2B3+CYP3A1                    278 ± 20      377 ± 11^∗^                      1.36
  By varying UDPGA concentration                                                  
  UGT2B3                           982 ± 70      664 ± 20                         0.676
  UGT2B3+CYP3A1                    1088 ± 103    356 ± 14^∗^                      0.327

Data were fitted to a Michaelis-Menten equation (

Figure

2

). Results are the estimated value ± SE.

∗

Significantly different from UGT2B3 single expression (

p

\< 0.0001).

![**Michaelis-Menten plots of 4-MU glucuronidation catalyzed by UGT2B3(S316N) in the absence and presence of CYP3A1 co-expression.** The plots for UGT2B3(S316N) single- and UGT2B3(S316N)-CYP3A1-dual are shown. The kinetics obtained by varying the 4-MU concentration **(A)** and UDPGA concentration **(B)** are shown. In **(A)**, the 4-MU concentration was varied over the range 10-1000 μM while the UDPGA concentration was fixed at 2 mM. In **(B)**, the UDPGA concentration was varied over the range 50 μM--7.5 mM while the 4-MU concentration was fixed at 1 mM. The total amount of protein added to the assay mixture was standardized at 100 μg. For this, when necessary, control baculosomes were added to the reaction mixture. The kinetic parameters were calculated by fitting the curve to a Michaelis-Menten equation, and they are listed in **Table [2](#T2){ref-type="table"}**.](fphar-07-00427-g003){#F3}

###### 

Kinetic parameters for 4-MU glucuronide formation catalyzed by Sf-9 microsomes expressing UGT2B3(S316N) alone and UGT2B3(S316N) + CYP3A1: kinetics by varying 4-MU or UDPGA concentration.

                                   *K*~m~ (μM)     *V*~max~ (pmol/min/mg protein)   CLint (μg/min/mg protein)
  -------------------------------- --------------- -------------------------------- ---------------------------
  By varying 4-MU concentration                                                     
  UGT2B3(S316N)                    330 ± 33        143 ± 6                          0.433
  UGT2B3(S316N)+CYP3A1             444 ± 43        329 ± 43^∗^                      0.740
  By varying UDPGA concentration                                                    
  UGT2B3(S316N)                    513 ± 51        142 ± 4                          0.277
  UGT2B3(S316N)+CYP3A1             1040 ± 100^∗^   256 ± 8^∗^                       0.245

Data were fitted to a Michaelis-Menten equation (

Figure

3

). Results are the estimated value ± SE.

∗

Significantly different from UGT2B3(S316N) single expression (

p

\< 0.0001).

Effect of EndoH-Treatment on the Activity of UGT2B3(S316N)
----------------------------------------------------------

The glucuronidation activities of microsomes expressing UGT alone, UGT2B3(S316N), and UGT and CYP, UGT2B3(S316N)-CYP3A1, were compared with or without EndoH-treatment (**Figure [4](#F4){ref-type="fig"}**). The 4-MU glucuronidation activity in UGT2B3(S316N)-CYP3A1 was significantly higher than the UGT2B3(S316N) single expression even after treatment with EndoH. The deglycosylation did not affect the activity of UGT2B3(S316N).

![**Effect of EndoH-treatment on the glucuronidation catalyzed by UGT2B3(S316N).** Baculosomes (20 μg protein) from UGT2B3(S316N) single- and UGT2B3(S316N)-CYP3A1 dual-expressing Sf-9 cells were treated with Endoglycosidase H (EndoH, 250 U) at 37°C for 1 h. The UGT activity was assayed with 100 or 1000 μM 4-MU and UDPGA fixed at 3 mM. Significantly different from UGT2B3(S316N) single expression (^∗∗^*p* \< 0.001; ^∗∗∗^*p* \< 0.0001).](fphar-07-00427-g004){#F4}

Protein--Protein Interaction of CYP3A1 and UGT2B3/UGT2B3(S316N)
---------------------------------------------------------------

(His)~6~-tagged CYP3A1 was constructed and, the baculovirus encoding it subsequently co-transfected with either UGT2B3 or UGT2B3(S316N) which were tagged with HA. A band immunoreactive to an anti-HA antibody was observed in the precipitates (**Figure [5](#F5){ref-type="fig"}**). However, there was no pull down when they were expressed singly. Therefore, both HA-tagged UGT2B3 and UGT2B3(S316N) were pulled down by (His)~6~-tagged CYP3A1 which suggests that CYP3A1 interacts with not only UGT2B3 but also UGT2B3(S316N).

![**Detection of an interaction between CYP3A1 and UGT2B3/UGT2B3(S316N) by His-tag pull-down assay.** UGT2B3-HA and UGT2B3(S316N)-HA were expressed in the presence and absence of coexpressed His-CYP3A1. The pull-down assay was performed according to methods previously published ([@B16]) with slight modification. Microsomes (2 mg protein/mL) were solubilized with sodium cholate. Then the solubilized microsomes were used in each assay. His-CYP3A1 and proteins trapped by this P450 were eluted with buffer containing imidazole at a high concentration. Each protein was detected by immunoblotting with a specific antibody: rabbit anti-HA or rabbit anti-His. Solubilized microsomes and His-CYP3A1--trapped samples are indicated as Input (30% of the input) and PD (pull down), respectively. In **(A)**, HA-tagged wild-type UGT2B3 (WT-HA) was used. In **(B)**, HA-tagged UGT2B3(S316N) (MT-HA) was used. WT-HA+CYP-His and MT-HA+CYP-His indicate microsomes coexpressing UGT2B3-HA or UGT2B3(S316N)-HA with His-CYP3A1, respectively. Duplicate assays were carried out. For each pull-down sample, one half of the precipitate was subjected to SDS-PAGE for detection with either HA or His while the lanes shown by "C" represent a negative control sample obtained by the same procedures but using solubilized control microsomes as an input, with microsomes prepared from Sf-9 cells transfected with control baculovirus alone. Details are described in the Section "Materials and Methods".](fphar-07-00427-g005){#F5}

Prediction of the Structure of the Carboxyl Terminal Domain of Wild-Type UGT2B3 and a Glycosylated Mutant UGT2B3(S316N)
-----------------------------------------------------------------------------------------------------------------------

The structures of part of the carboxyl terminal domain of UGT2B3 and UGT2B3(S316N) were predicted by *Phyre^2^* with UGT2B7 as template (**Figure [6](#F6){ref-type="fig"}**). For comparison, the structure of UGT2B3 which has Asn at 316 as a potential *N-*glycosylation site was also predicted. For reference, the prediction was also carried out for the UGT2B7 and UGT2B2 with UGT2B7 as a template. In UGT2B7, Asn 315 is the corresponding residue. Overall, it seems that the predicted structures are very similar to each other. The structure around residue 316 or 315 (for UGT2B7), a β-strand structure was observed except for UGT2B3. Although the prediction does not include the effect of the glycosylation chain, it is assumed that substitution of Ser 316 for Asn altered the partial structure of UGT2B3.

![**Comparison of the predicted structure of UGT2B3 wild-type, UGT2B3(S316N), UGT2B2, and UGT2B7: the region spanning from 285 to 450.** The models were constructed using the Phyre2 web server ([@B8]) with the UGT2B7 (amino acid residue from 285 to 450) as a template. Template: UGT2B7, [@B15] (DOI: 10.2210/pdb2o6l/pdb).](fphar-07-00427-g006){#F6}

Discussion
==========

The effect of CYP3A1 on UGT2B3 which lacks a potential glycosylation site was studied. Since it is evident that CYP3A1 modulates UGT2B3 activity, *N-*glycosylation is not essential for CYP3A1 to modulate this UGT. Furthermore, this study demonstrates that the introduction of *N-*glycosylation to UGT2B3 alters UGT sensitivity to a functional protein--protein interaction with CYP3A: wild-type UGT2B3 which lacks*N-*glycosylation sites is suppressed by CYP3A1, whereas this P450 increases UGT2B3(S316N) activity. These results suggest that although the *N-*glycosylation of UGT is not essential for modulation by CYP3A, the *N-*sugar chain linked to UGT is one of the factors regulating this interaction between CYP3A and UGT. In this study, we focused on the effect of CYP3A1 on UGT function. To allow a comparison, we carried out several transfection experiments to obtain microsomes for UGT single and CYP3A1-UGT dual microsomes with a comparable UGT level and the results shown in **Tables [1](#T1){ref-type="table"}** and **[2](#T2){ref-type="table"}** allow an examination of the effect of CYP3A1 on each UGT. Although the activity of UGT2B3 and UGT2B3(S316N) cannot be simply compared between **Tables [1](#T1){ref-type="table"}** and **[2](#T2){ref-type="table"}**, it seems that the introduction of *N-*glycosylation to UGT2B3 at this position reduces the glucuronidation activity. Based on this, it is likely that CYP3A1 increases the function of the glycosylated mutant UGT2B3(S316N) to approach that of the wild type. In general, the methods that involve introduction of mutation(s) to the potential glycosyation site to inhibit glycosylation are a well-known strategy to investigate the role of glycosylation on enzyme function. In some enzymes, the activity was increased by reducing the glycosylation site, while in some other enzymes, the activity was decreased ([@B24]). *N-*Glycosylation is involved in the protein folding of UGT1A9 and important for catalytic function ([@B21]). However, deglycosylation of the mature UGT1A9 did not affect its function. In the case of UGT2B3(S316N), *N-*glycosylation resulted in positive modulation by CYP3A1 (**Figure [4](#F4){ref-type="fig"}**). However, the increase in UGT activity was consistent even after EndoH-treatment (**Figure [4](#F4){ref-type="fig"}**). Therefore, it is suggested that the engineered glycosylated chain of UGT2B3(S316N) is no longer required after maturation and fixing the conformation of UGT2B3(S316N). This was also true for UGT2B3(S316N) without co-expression of CYP3A1. Taken together, these findings suggest that the complex formation with CYP3A1 affects the conformation of UGT2B3(S316N). Although the kinetics were not studied when examining the effect of deglycosylation, the activity was consistent at both low and high substrate concentrations. It is assumed that deglycosylation did not alter the affinity to the substrate. Since glycosylation of UGT has been shown to be important during synthesis of the enzyme but not once the mature enzyme is formed ([@B21]), it is assumed that the CYP3A1-dependent modulation of UGT2B3(S316N) that we observed is due to the interaction of CYP3A4 with the secondary structure of UGT2B3(S316N) during the process of formation of the mature UGT enzyme. However, whether glycosylation or merely the presence of the Asn at that site is sufficient to alter structure and function, remains to be clarified in a future study. Nevertheless, our current study suggests that the introduction of a potential glycosylation site to UGT2B3 alters its CYP3A1-dependent modulation.

UGT2B7 is known to interact with CYP3A4 ([@B25], [@B26]; [@B16]). Furthermore, the crystal structure of the cofactor-binding domain of UGT2B7 (from residues 285 to 450) has been determined ([@B15]). So far, that is the sole example of a crystal structure of mammalian UGTs. Concerning the structural differences between UGT2B3 and UGT2B3(S316N), the structures of the corresponding region were predicted by *Phyre^2^* with UGT2B7 as a template (**Figure [6](#F6){ref-type="fig"}**). The results were very similar except around the 316th residue. So, on the basis of the prediction, the substitution of Ser at the 316th residue of UGT2B3 by Asn converted the random coil to a β-strand structure (**Figure [6](#F6){ref-type="fig"}**). It is reasonable to suppose that the combination of the structural difference and the *N-*glycosylation in UGT2B3(S316N) resulted in a different susceptibility to modulation by CYP3A1.

This study suggests that *N-*glycosylation of UGT is one of the determinants of the functional interaction between CYP3A and UGT. UGT function is known to be affected by *N-*glycosylation ([@B12],[@B13]; [@B1]; [@B21]; [@B19]). Many UGTs have *N-*glycosylation at more than two positions ([@B1]; [@B19]). Therefore, the role of *N-*glycosylation of the other UGTs is very important for functional protein--protein interactions with CYP3A. Further studies are necessary to determine the importance of *N-*glycosylation of UGTs in the UGT-CYP interactions.
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